Novartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.
A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision on approval by Oct. 3.
Can this treatment be applied to Lymphoma?
Yes, CTL019 can work against any malignancy that expresses CD19, which would be any B cell malignancy such as ALL, CLL, and various B cell lymphomas. It also works against multiple myeloma, but they are not certain why it works. It either attacks a CD19+ precursor, or MM cells express CD19 briefly or at low levels and get killed off.
You should know the truth about CANCER. There are so many different therapies & drugs out there, far better to avoid Cancer. Spirit know what causes CANCER so people are not confused about it.
Comments are closed.